|Published (Last):||28 December 2005|
|PDF File Size:||4.38 Mb|
|ePub File Size:||3.81 Mb|
|Price:||Free* [*Free Regsitration Required]|
Background: Predefined response and remission criteria may hold more clinical relevance than mean scores on rating scales. Analysis was by intention-to-treat. Comparisons with haloperidol showed a better chance for remission on amisulpride HR 2.
Conclusions: Substantial proportions of first-episode patients with schizophrenia showed clinically meaningful response and remission rates within 12 months. The proportions of response and remission were higher for most SGAs as compared to haloperidol.
Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.
Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily.
Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Full-text links Cite Favorites. Abstract Background: Predefined response and remission criteria may hold more clinical relevance than mean scores on rating scales. Similar articles Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Kahn RS, et al. Volavka J, et al. J Clin Psychiatry. Pijnenborg GH, et al. Eur Neuropsychopharmacol. Epub Apr Using antipsychotic agents in older patients. Alexopoulos GS, et al. PMID: Review. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Soares-Weiser K, et al. Epub May Show more similar articles See all similar articles.
Cited by 30 articles Common increased hippocampal volume but specific changes in functional connectivity in schizophrenia patients in remission and non-remission following electroconvulsive therapy: A preliminary study. Jiang Y, et al. Neuroimage Clin. Epub Nov 8. Bozzatello P, et al. Front Psychiatry. Evaluation of SYA as a new potential antipsychotic agent without catalepsy. Bricker BA, et al. Pharmacol Biochem Behav. Epub Feb Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis.
Zisman-Ilani Y, et al. BMC Psychiatry. Zhang X, et al. Neurosci Bull. Show more "Cited by" articles See all "Cited by" articles. Publication types Multicenter Study Actions. Randomized Controlled Trial Actions. Research Support, Non-U. Gov't Actions. MeSH terms Adolescent Actions. Adult Actions. Cross-Cultural Comparison Actions. Dose-Response Relationship, Drug Actions.
Europe Actions. Female Actions. Humans Actions. International Cooperation Actions. Israel Actions. Male Actions. Outcome Assessment, Health Care Actions. Predictive Value of Tests Actions.
Proportional Hazards Models Actions. Psychiatric Status Rating Scales Actions. Retrospective Studies Actions. Secondary Prevention Actions. Time Factors Actions. Young Adult Actions. Substances Antipsychotic Agents Actions. Full-text links [x] Elsevier Science. Copy Download.
The European First Episode Schizophrenia Trial (EUFEST): Rationale and Design of the Trial
Background: Predefined response and remission criteria may hold more clinical relevance than mean scores on rating scales. Analysis was by intention-to-treat. Comparisons with haloperidol showed a better chance for remission on amisulpride HR 2. Conclusions: Substantial proportions of first-episode patients with schizophrenia showed clinically meaningful response and remission rates within 12 months. The proportions of response and remission were higher for most SGAs as compared to haloperidol.
WEIGHT GAIN AND ANTIPSYCHOTICS. DATA FROM EUFEST STUDY.
Background: Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested. These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics. Aims: The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.